Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Authors :: Scott Antonia
Luigi Manenti
Felipe K. Hurtado
Mehreteab Aregay
Erick Morris
Liza Morgan
Julio Castro
Theresa A. Boyle
Amer A. Beg
Dung Tsa Chen
Zhihua Chen
Margaret L. Barlow
Ram Thapa
Eric B. Haura
Jhanelle E. Gray
Tawee Tanvetyanon
Ben Creelan
Alberto A. Chiappori
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Full Text Access

Tools